Sleep-disordered breathing and hypertension: Past lessons, future directions

Sleep

Volumn 20, Issue 9, 1997, Pages 806-811

  Guilleminault, Christian ^a,b   Robinson, Anstella ^a  

^a STANFORD UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Blood pressure; Endothelium related vasodilation; Genetics of blood pressure; Obstructive sleep apnea syndrome

Indexed keywords

VASCULOTROPIN;

BLOOD PRESSURE REGULATION; HEREDITY; HUMAN; HYPERTENSION; NONHUMAN; PLETHYSMOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SLEEP APNEA SYNDROME; SYMPATHETIC TONE; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0030724484     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: 10.1093/sleep/20.9.806     Document Type: Review

References (47)

1. Coccagna G, Mantovani M, Brignani P, Parchi C, Lugaresi E. Tracheostomy in hypersomnia with periodic breathing. Bull Physiol Pathol Respir 1972;8:1217-28.
2. Guilleminault C, Dement WC, Monod N. Syndrome "mon subite du Nourrisson": apnees au cours du sommeil, nouvelles hypotheses. Nouv Pres Med 1973;2:1355-8.
3. Guilleminault C, Eldridge F, Simmons FB, Dement WC. Sleep apnea syndrome: can it induce hemodynamic changes. West J Med 1975;123:7-16.
4. Guilleminault C, Eldridge F, Simmons FB, Dement WC. Sleep apnea in eight children. Pediatrics 1976;58:23-30.
5. Motta J, Guilleminault C, Schroeder JS, Dement WC. Tracheostomy and hemodynamic changes in sleep induced apnea. Ann Intern Med 1978;89:454-8.
6. Guilleminault C, Stoohs R. Arousal, increased respiratory efforts, blood pressure and obstructive sleep apnea. J Sleep Res 1995;4:5117-24.
7. Gastaut H, Tassinari CA, Duron B. Etude polygraphique des manifestations épisodiques (hypniques et respiratoires) diurnes et nocturnes, du syndrome de Pickwick. Rev Neurol (Paris) 1965;112:573-9.
8. Sadoul P, Lugaresi E. Hypersomnia with periodic breathing: a symposium. Bull Physiol Pathol Respir 1972;8:967-1292.
9. Carroll D. Nosology of "Pickwickian Syndrome". Bull Physiol Pathol Respir 1972;8:1241-8.
10. Wilcox J, Grunstein RR, Hedner JA, et al. Effect of nasal CPAP during sleep on 24 hour blood pressure in obstructive sleep apnea. Sleep 1993;16:539-44.
11. Suzuki M, Otsuka K, Guilleminault C. Long term nasal CPAP administration can normalize hypertension in obstructive sleep apnea patients. Sleep 1993;16:545-9.
12. Waller PC, Bothal RS. Is snoring a cause of vascular disease? An epidemiological review. Lancet 1989;1:143-6.
13. Hla KM, Young TB, Bidwell T, Palta M, Skatrud JB, Dempsey J. Sleep apnea and hypertension. A population-based study. Ann Intern Med 1994;120:382-8.
14. Strohl K, Saunders NA, Feldman NT, Hallett M. Obstructive sleep apnea in family members. N Engl J Med 1978;299:969-73.
15. Guilleminault C, Powell N, Heldt G, Riley R. Small upper airway in near miss SIDS infants and their families. Lancet 1986; 1:402-7.
16. Wittig RM, Zorick FR, Roehrs TA, Sicklesheel AM, Roth T. Familial childhood sleep apnea. Henry Ford Hosp Med J 1988; 36:13-5.
17. Redline S, Tosteson T, Tischler PV, Carskadon MA, Millman RP. Studies in the genetics of obstructive sleep apnea: familial aggregation of symptoms associated with sleep disordered breathing. Am Rev Respir Dis 1992;145:440-4.
18. Guilleminault C, Partinen M, Hallman K, Powell NB, Stoohs R. Familial aggregates in obstructive sleep apnea syndrome. Chest 1995;107:1275-82.
19. Ward R. Familial aggregation and genetic epidemiology of blood pressure. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology diagnosis and management. New York: Raven Press, 1990:81-100.
20. Schork NJ, Krieger JE, Trolliet MR, et al. A biometrical genome search in rats reveals the multigenic basis of blood pressure variation. Genome Res 1995;5:164-72.
21. Somers VK, Mark AL, Abboud FM. Sympathetic activation by hypoxia and hypercapnia implication for sleep apnea. Clin Exp Hypertens 1988;10:413-22.
22. Carlson J, Hedner J, Elam M, Ejnell H, Sellgreen J, Wallin G. Augmented resting sympathetic activity in awake patient with obstructive sleep apnea. Chest 1993;103:1763-8.
23. Hedner J, Darpo B, Ejnell H, Carlson J, Caidahl K. Reduction in sympathetic activity after long term CPAP treatment in sleep apnea - cardiovascular implications. Eur Respir J 1995;8:222-9.
24. Waravdekar NV, Levenberger WA, Sinoway L, Zwillich CW. Impact of nasal CPAP therapy on muscle nerve sympathetic activity in sleep apnea syndrome. Am J Respir Crit Care Med 1994;149:A808 (abstract).
25. Hedner JA, Wilcox J, Sullivan CE. Speculations on the interaction between vascular disease and obstructive sleep apnea. In: Saunders NA, Sullivan CE, eds. Sleep and breathing, 2nd edition. New York: Marcel Dekker, 1994:823-46.
26. Fletcher EC, Lesske J, Quian W, Millar CC, Unger T. Repetitive episodic hypoxia causes diurnal elevation of blood pressure in rats. Hypertension 1992;19:555-61.
27. Fletcher EC, Lesske J, Culman J, Millar CC, Unger T. Sympathetic denervation blocks blood pressure elevation in episodic hypoxia. Hypertension 1992;20:612-9.
28. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cell. Biochem Biophys Res Commun 1989;161:851-9.
29. Ferrara N, Houck KA, Jakeman L, Leung DW. Molecular and biological properties of the vascular growth factor family of proteins. Endocr Rev 1992;13:18-32.
30. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of an alternative splicing of RNA. Mol Endocrinol 1991;5:1806-14.
31. de Vries C, Escobedo JA, Veno H, Houck KA, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for endothelial growth factor. Science 1992;255:989-91.
32. Terman BI, Vernmazen MD, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem Biophvs Res Commun 1992;34:1578-86.
33. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute and chronic hypoxia-modulation of gene expression by nitric oxide. J Clin Invest 1995;95:1798-807.
34. Ku DO, Zaleski JK, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 1993;265:H586-92.
35. Roberts WG, Palade G. Increased microvascular permeability and endothelial fenestration induced by endothelial growth factor. J Cell Phvsiol 1995;108:2369-79.
36. Yang R, Thomas GR, Bunting S, et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 1996;27:838-44.
37. Moncada S, Rees DD, Schulz R, Palmer RMJ. Development and mechanisms of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric-oxide in vivo. Proc Natl Acad Sci 1991;88:2166-70.
38. Hedner J, Carlson J, Rangemark C. Reduced endothelium dependent vascular relaxation in patients with sleep apnea. J Sleep Res 1994;Suppl 1:101 (abstract).
39. Duchna HW, Moreno H, Robinson A, et al. Vascular responsiveness to bradykinin and nitroglycerin in patients with obstructive sleep apnea syndrome. Preliminary results of an invivo study. J Sleep Res 1997;26:98 (abstract).
40. Aellig WH. A new technique for recording compliance of human hand veins. Br J Clin Pharmacol 1981;11:237-43.
41. Auch-Schwelk W, Kuchenbuch C, Claus M, et al. Local regulation of vascular tone by bradykinin and angiotensin converting enzyme inhibitors. Eur Heart J 1993;14:154-60.
42. Bedarida G, Kim D, Hoffman BB, Blaschke TF. Characterization of an inhibition of nitric oxide synthase in human hand veins. Horm Metab Res 1994;26:109-12.
43. Dachman WD, Ford GA, Blaschke TF, Hoffman BB. Mechanism of bradykinin induced venodilation in humans. J Cardiovasc Pharmacol 1993;21:241-8.
44. Ford GA, Vestal RE, Hoffman BB, Blaschke TF. Age related changes in adenosine and beta-adrenoreceptor responsiveness of vascular smooth muscle in man. Br J Clin Pharmacol 1992;33: 83-7.
45. Pan HYM, Hoffman BB, Pershe RA, Blaschke TF. Decline in beta adrenergic receptor mediated relaxation with aging in man. J Pharmacol Exp Ther 1986;239:802-7.
46. Furchgott RF. The role of endothelium in the response of vascular smooth muscle to drug. Annu Rev Pharmacol Toxicol 1984;24:175-97.
47. Luscher TF, VanHoutte PM. The endothelium: modulation of cardiovascular function. Boston: CRC Press, 1990:23.